Free 24-hour delivery over £60 · Same-day despatchOrder before 2pm - same-day despatch · Free 24-hour delivery over £60
Research use only
All lyophilised (powdered) products and any related items sold by Kovalabs are strictly for scientific research purposes. No dosing guidelines are supplied with any product. We comply with all local regulations governing research-only sales within the United Kingdom. We are not a pharmacy and do not endorse, offer, or provide advice for human or animal consumption. International customers are responsible for checking their own local laws and regulations before purchasing.
You must be 18 or over and purchasing for scientific research only.
By clicking ‘I agree’ you confirm you have read and accepted the terms set out in this disclaimer.
Research use only
· 8 min read
Most peptides do not survive a trip through stomach acid - dissolving on contact is rather why the injectable ones get injected. BPC-157 is the exception its own paperwork advertises: a 15-residue fragment of a protein found in human gastric juice, reported to be stable in that same gastric juice, which is why the literature files it under the "stable gastric pentadecapeptide." The name "Body Protection Compound" is doing a lot of marketing work; what the molecule actually is, chemically, is a synthetic partial sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) with no cysteines, no disulfide bridges and an unusually flat stability profile. Kovalabs supplies it strictly as a research reagent; everything below describes what published studies investigated, not any human use, benefit or outcome.
| Compound | BPC-157 (Body Protection Compound 157) |
|---|---|
| Synonyms / dev codes | PL-14736, PLD-116, PL-10, Bepecin, H-GEPPPGKPADDAGLV-OH |
| Class | Synthetic pentadecapeptide; a partial sequence of the gastric juice protein BPC |
| Amino-acid sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Molecular formula | C62H98N16O22 |
| Molecular weight | 1419.5 g/mol (average) |
| CAS number | 137525-51-0 |
| PubChem CID | 9941957 |
| Supply status | Research use only - not for human or veterinary use |
BPC-157 is the pentadecapeptide H-Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val-OH (single-letter GEPPPGKPADDAGLV): fifteen residues, no cysteine, therefore no disulfide bond to reduce or scramble. PubChem CID 9941957 is the record to verify against; it carries the molecular formula C62H98N16O22, an average molecular weight of 1419.5 g/mol, CAS 137525-51-0, and the full sequence as a synonym. Name-to-CID, CAS-to-CID and sequence-to-CID all resolve to the same molecule.
One identity caution worth stating plainly, because it is a trap we have seen sprung: a bare database search for "BPC-157" can surface chemically unrelated records, and a confident-looking but wrong identifier on a spec sheet is worse than none. The CAS-anchored record (CID 9941957, C62H98N16O22, 1419.5 g/mol) is the one to round-trip against; the mass and sequence on a lot certificate of analysis should match it rather than be taken on trust. The peptide is also supplied in different counterion states - the free base and the acetate or trifluoroacetate salt carry different masses - so confirm the salt form against the lot documentation.
| Property | Value | Resolution path |
|---|---|---|
| PubChem CID | 9941957 | Name, CAS and sequence lookups all converge |
| CAS number | 137525-51-0 | Listed in the CID 9941957 synonym set |
| Molecular formula | C62H98N16O22 | PubChem compound record |
| Molecular weight | 1419.5 g/mol | PubChem compound record |
| Sequence (15-mer) | GEPPPGKPADDAGLV | Synonym / canonical structure |
| Disulfide bonds | None (no cysteine residues) | Derived from sequence |
BPC-157 did not come from rational receptor design. It is a synthesised partial sequence of a larger protein the originating group - Sikiric and colleagues in Zagreb - reported isolating from gastric juice and named Body Protection Compound. The 15-mer is the fragment they took forward, and it later carried the pharmaceutical development code PL-14736 into clinical-stage research. Two honest framing points belong up front. First, provenance: the overwhelming majority of the primary literature originates from that single group, the bulk of the experimental work is in rodent models, and independent replication outside the originating group is limited - a 2025 literature-and-patent review notes both the breadth of the preclinical model list and the heavy patent footprint around the molecule. Second, the property the name does not advertise but the chemistry does: reported stability in human gastric juice and in aqueous solution without a carrier is the genuinely unusual, genuinely verifiable feature, and it is a physicochemical observation rather than any statement about use.
The mechanistic literature for BPC-157 is largely review-level and hypothesis-generating, and it is fair to read it as such. Three threads recur. The nitric-oxide (NO) system is the most developed: review work frames BPC-157 in relation to NO generation, the L-arginine / NO pathway and endothelial function (Sikiric et al., Curr Pharm Des 2014; PMID 23755725). A vascular / angiogenic thread runs alongside it, discussing the peptide in the context of blood-vessel biology and standard angiogenic growth factors such as VEGF (Seiwerth et al., Curr Pharm Des 2014, PMID 23782145; Seiwerth et al., Curr Pharm Des 2018, PMID 29998800). A third thread places it on the brain-gut axis and, separately, the central nervous system (Sikiric et al., Curr Neuropharmacol 2016, PMID 27138887; Vukojevic et al., Neural Regen Res 2022, PMID 34380875). These are proposed mechanisms catalogued in review articles; none is reproduced here as an established effect, and no human-relevant outcome is drawn from any of them.
The BPC-157 literature is large and heavily preclinical. Each entry below is stated as study design and the named endpoint only. No result, effect size, direction or benefit is reproduced, and the rodent-model endpoints are named generically as the measured variables.
The pattern to take from this list is structural, not clinical: a broad preclinical model set, concentrated in one research lineage, weighted toward rodent work, with review articles outnumbering independent replications. That is research context, not a set of findings a reader should expect to hold.
For transparency about study design, the table below records the amounts the cited studies administered to animals or applied to cells. It is a record of what researchers used, not a protocol, recommendation or instruction for any use in humans or animals. BPC-157 is supplied as a research reagent only, and no human dose is stated, recommended or implied anywhere on this page.
| Study / system | Administered in the study | Notes |
|---|---|---|
| Rat model (Kralj et al., Biomedicines 2021; PMID 35052769) | 10 mcg/kg and 10 ng/kg (in vivo) | The dose pair that recurs across much of the originating group's rodent work |
| Cell culture (same study) | 0.16 mcg/mL and 0.16 ng/mL (in vitro) | Concentrations applied to cultured cells |
The 10 mcg/kg and 10 ng/kg pairing is the regimen reported again and again throughout the rodent literature on this peptide. These are the quantities used in the cited work, reproduced so the study design is transparent; they are not a dose for any person or animal, and nothing here describes a route, schedule or protocol for use.
This is the section to weigh most heavily, because the BPC-157 literature is easy to overstate. The solid part is the chemistry and provenance: BPC-157 is a defined 15-residue sequence derived from a gastric-juice protein, and its reported stability in gastric juice and in plain aqueous solution is genuinely unusual and independently verifiable. The middle ground is the mechanism work - the nitric-oxide-system, angiogenic and brain-gut hypotheses - which is interesting but overwhelmingly review-level and rodent, drawn largely from a single research lineage, and a tendon fibroblast in a culture dish is not a person. The weakest part is the human evidence: despite an old pharmaceutical development code (PL-14736), rigorous controlled human data is essentially absent. So the honest summary: BPC-157 is a real, well-characterised molecule with an interesting but single-source and largely preclinical research record. It is not a licensed medicine, and it has not been shown to produce defined outcomes in humans. Curiosity is warranted; certainty is not.
The notes below are general physicochemical and storage information for bench work only. They are not dosing, administration or use instructions, and nothing here describes a preparation for use in humans or animals.
BPC-157 is typically supplied as a white lyophilised powder, commonly as the acetate salt. As a hydrophilic 15-residue peptide with no cysteine and therefore no disulfide bond, it dissolves readily in aqueous laboratory solvents and avoids the oxidation-and-scrambling failure modes that complicate cysteine-containing peptides - which is a large part of why it is comparatively forgiving to handle. Standard short-peptide practice applies: store the sealed lyophilate desiccated, cold and protected from light, with long-term storage frozen; equilibrate vials to room temperature before opening to limit condensation; reconstitute in an appropriate aqueous solvent and aliquot to avoid repeated freeze-thaw cycles. See the reconstitution guide for the standard workflow. Purity, mass and identity for each lot are documented on its certificate of analysis and should be verified against the figures above rather than assumed. Researchers working across the tissue-repair set often cross-reference TB-500 (the comparison is set out in the BPC-157 vs TB-500 reference) and the copper peptide GHK-Cu, within the tissue-repair research category.
Kovalabs supplies BPC-157 strictly as a research chemical for laboratory research use only. It is not a medicine, supplement or veterinary product, is not for human or veterinary use, and nothing on this page constitutes a medicinal, therapeutic, healing, efficacy, dosing or human-outcome claim. It has not been evaluated by the MHRA or any comparable regulator for safety or efficacy in humans or animals. The descriptions above are restricted to chemistry and to study designs and endpoint names, stated only as what each study investigated. Every batch is third-party tested with a certificate of analysis. Purchasers are responsible for handling, storing and using the material in compliance with all applicable laws and institutional requirements. Full terms are on the research disclaimer page.
BPC-157 is a synthetic pentadecapeptide (15 amino acids), Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, described in the literature as a partial sequence of a gastric juice protein termed Body Protection Compound. It is supplied for research use only and is not for human or veterinary use.
PubChem CID 9941957, CAS 137525-51-0, molecular formula C62H98N16O22 and an average molecular weight of 1419.5 g/mol. These cross-check by name, CAS and sequence lookup. The peptide has no cysteine and so no disulfide bond; salt forms (free base vs acetate or trifluoroacetate) differ in mass, so confirm the form against the lot certificate of analysis.
Because the literature reports it as stable in human gastric juice and in aqueous solution without a carrier - unusual for a short peptide. That is a physicochemical stability description of the molecule, not a statement about any use, route or effect.
Published designs name endpoints such as in-vitro tendon-fibroblast outgrowth, survival and migration (PMID 21030672) and intestinal permeability markers in a rodent model (PMID 32445447), alongside review articles proposing nitric-oxide-system, angiogenic and brain-gut mechanisms (PMID 23755725, 23782145, 29998800, 27138887). These are named endpoints and proposed mechanisms only; no result or outcome is asserted, and the primary literature is concentrated in one research group and weighted toward animal models.
By convention for short synthetic peptides: store the lyophilised powder sealed, desiccated, cold and out of light, frozen for long-term storage, and equilibrate to room temperature before opening. For bench use it is dissolved in an appropriate aqueous laboratory solvent and aliquoted to avoid freeze-thaw cycling. See the reconstitution guide. This is bench handling of a reagent, not a preparation method for any use in humans or animals.
No. BPC-157 is supplied as a research chemical for laboratory use only. It is not approved as a medicine by the MHRA or any comparable regulator, is not for human or veterinary use, and nothing on this page is a medicinal, therapeutic, healing or efficacy claim. See the research disclaimer for full terms.
The publication titles below are the original authors' own titles, reproduced so each citation can be verified against PubMed and the cited DOI. They are not statements, conclusions or claims by Kovalabs, and the body of this page describes each study by its design and endpoint name only.